Design of solid lipid nanoparticles as a feasible alternative for treatment of pulmonary infections

ISLAN GA; DURAN N; CASTRO GR

Trivandrum

Conferencia; International Conference on New Horizons in Biotechnology (NHBT-2015); 2015

CSIR-National Institute for Interdisciplinary Science and Technology Trivandrum, Kerala, INDIA

The purpose of the present work is thedevelopment of an effective antibiotic delivery device base on solid lipid nanoparticles(SLN) for treatment of pulmonary infections. Levofloxacin, a hydrophilic widespectrum antibiotic, commonly used against lung infections was selected as themodel antibiotic. At the present, its encapsulation in SLN has not beencompletely investigated and could be a feasible carrier to reach the deepestsites of lungs, avoiding in situcrystallization of the drug. SLN of miristyl miristate were prepared bysonication method at different environmental conditions and characterized bydynamic light scattering, optical, transmission and scanning electron microscopyfor size and morphology. SLN showed a 20.1 ±1.4 % encapsulation efficiency, whichrepresents 5 µg of Levofloxacin per mg of SLN. In vitro studies showed that SLN formulation exhibit a controlledrelease profile with a biphasic drug release pattern with burst release of 80 %at the initial 5 hours and prolonged release afterwards for two days. Thehydrodynamic mean diameter and zeta potential of SLN were 182.6 ±3.2 nm and-10.2 ±0.2 mV. The developed formulation was stable for up to 90 days at 5ºCand showed an active antimicrobial activity against common lung opportunisticpathogens like Pseudomonas aeruginosaand Staphylococcus aureus.